Lexeo Therapeutics (LXEO) reported second-quarter 2026 financial results and operational updates, including a net loss of $25.9 million, or $0.30 per share basic and diluted, for the three months ended June 30, 2026.
The company said it ended the quarter with $234.2 million in cash, cash equivalents and investments, expected to fund operations into 2028. Lexeo also initiated SUNRISE-FA 2 for LX2006 in June and received FDA RMAT designation for LX2020 in August.
- Cash, cash equivalents and investments totaled $234.2 million as of June 30, 2026.
- Research and development expenses were $19.0 million for the quarter, compared with $14.7 million a year earlier.
- General and administrative expenses were $9.0 million, compared with $16.0 million in the prior-year quarter.
- Net loss was $25.9 million, compared with $26.1 million for the three months ended June 30, 2025.
- SUNRISE-FA 2 enrolled its first patient in June, with topline data expected in the second half of 2027.
- LX2020 received FDA RMAT designation based on interim clinical data in PKP2 arrhythmogenic cardiomyopathy.
$LXEO Insider Trading Activity
$LXEO insiders have traded $LXEO stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $LXEO stock by insiders over the last 6 months:
- RICHARD NOLAN TOWNSEND (Chief Executive Officer) has made 0 purchases and 4 sales selling 94,462 shares for an estimated $511,230.
- NARINDER PAL BHALLA (Chief Medical Officer) sold 22,306 shares for an estimated $98,592
- JOSE MANUEL OTERO (Chief Operating Officer) has made 0 purchases and 3 sales selling 8,984 shares for an estimated $46,803.
- LOUIS EDWARD TAMAYO (Chief Financial Officer) sold 4,641 shares for an estimated $20,838
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$LXEO Hedge Fund Activity
We have seen 73 institutional investors add shares of $LXEO stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AFFINITY ASSET ADVISORS, LLC added 1,850,211 shares (+57.8%) to their portfolio in Q1 2026, for an estimated $10,620,211
- ORBIMED ADVISORS LLC added 1,477,450 shares (+69.5%) to their portfolio in Q1 2026, for an estimated $8,480,563
- AVORO CAPITAL ADVISORS LLC removed 1,425,000 shares (-43.2%) from their portfolio in Q1 2026, for an estimated $8,179,500
- PARADIGM BIOCAPITAL ADVISORS LP added 1,420,936 shares (+29.8%) to their portfolio in Q1 2026, for an estimated $8,156,172
- GOLDMAN SACHS GROUP INC added 1,168,030 shares (+149.4%) to their portfolio in Q1 2026, for an estimated $6,704,492
- STATE STREET CORP added 786,515 shares (+22.0%) to their portfolio in Q2 2026, for an estimated $3,661,227
- SPRUCE STREET CAPITAL LP added 753,593 shares (+430.6%) to their portfolio in Q1 2026, for an estimated $4,325,623
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
